Annals of Oncology 13:86-91, 2002
© 2002 European Society for Medical Oncology
Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?
1 Department of Medicine, Institut Gustave Roussy, Villejuif, France 2 Working Group for Biometry, Department of Internal Medicine 1, University of Cologne, Cologne, Germany 3 Department of Medicine, Karolinska Hospital, Stockholm, Sweden 4 University Medical Center Nijmegen, Nijmegen 5 Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands 6 KKSL 7 IMISE, University of Leipzig, Leipzig, Germany
Abstract
Background: Early adjustment of treatment may benefit the patient. In order to guide treatment adjustment, use of early response (ER) or early complete response (ECR), judged after the few initial cycles of chemotherapy, is common in pediatric and also adult Hodgkin's and non-Hodgkin's studies. Paradoxically, almost no data support this strategy.
Patients and methods: The influence of ECR on outcome was evaluated in three series of advanced Hodgkin's disease (HD), leading to a series of questions.
Results: The 1982 EORTC study assessed prospectively the time frame needed to reach an apparent complete response (CR) through repeated tumor measurements. In patients assessed at mid-treatment before the fifth cycle, both 15 year freedom from progression (FFP) and overall survival (OS) were superior in ECR patients compared with other patients continued on the same treatment (61% versus 37%; P < 0.001). A series of questions arise from these observations. Question 1: is the shortening of treatment detrimental? In a randomized Swedish trial, in one arm treatment was shortened in patients evaluated from the fifth cycle as ECR as compared with the standard eight cycles arm, 10 year cause-specific-survival (CSS) was 53 versus 69% [not significant (ns)]; 10 year OS 49% versus 58% (ns). Conversely, in the EORTC 20884 study, ECR patients given only six cycles did as well as patients entering CR later and, for this reason, given eight cycles (identical 6 year event-free survival 75%). Question 2: is early treatment adaptation in patients who failed to reach ER beneficial? In the French MDH 90 trial, 15% of children failed to reach ECR after four cycles; in these children only, anthra-cyclines plus alkylating agents were given and the dose of radiotherapy increased, improving the results observed in the previous trial. In the EORTC 20884 study, patients who failed to reach an ECR were switched earlier to involved field RT: their results matched those of ECR patients, at the difference of the previous trial. Question 3: is ER a predicting factor that can be used with any type of treatment? Probably not, based on the German Hodgkin's Lymphoma Study Group trial HD 9: ECR is highly dependent on specific interval from treatment start and on treatment intensity.
Discussion: More general questions stem from these results. Question 4: is the definition of ER secured? With conventional imaging, the different methods for response assessment at end treatment also lead to different response rates; the assessment in the middle of treatment itself and the use of newer imaging techniques may further increase the variation. Indeed, question 5 is: is ER a concept based on any biology? Correlation to markers, 99mTc uptake, PET and hematological tolerance might help to pinpoint how and why ER represents a surrogate for final outcome.
Conclusion: ER is a surrogate for final outcome, reflecting both tumor burden and activity. This predictability may, and possibly should, impact on treatment.
CT scan; early response; imaging; Hodgkin; minimal residual disease; PET scan; prognosis; response; tumor markers; (99mTc)-MIBI scintigraphy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. L. Schwartz, L. S. Constine, D. Villaluna, W. B. London, R. E. Hutchison, R. Sposto, S. E. Lipshultz, C. S. Turner, P. A. deAlarcon, and A. Chauvenet A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425 Blood, September 3, 2009; 114(10): 2051 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sanchez-Espiridion, A. Sanchez-Aguilera, C. Montalban, C. Martin, R. Martinez, J. Gonzalez-Carrero, C. Poderos, C. Bellas, M. F. Fresno, C. Morante, et al. A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples Clin. Cancer Res., February 15, 2009; 15(4): 1367 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma Blood, July 15, 2006; 108(2): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Carde The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side? J. Clin. Oncol., December 20, 2005; 23(36): 9058 - 9062. [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Mikhaeel, M. Hutchings, P. A. Fields, M. J. O'Doherty, and A. R. Timothy FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma Ann. Onc., September 1, 2005; 16(9): 1514 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Montalban, J. F. Garcia, V. Abraira, L. Gonzalez-Camacho, M. M. Morente, J. L. Bello, E. Conde, M. A. Cruz, R. Garcia-Sanz, J. Garcia-Larana, et al. Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group J. Clin. Oncol., May 1, 2004; 22(9): 1664 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Federico, M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. Colombat, S. Luminari, F. Fabbiano, et al. High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2320 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Rehwald, H. Schulz, M. Reiser, M. Sieber, J. O. Staak, F. Morschhauser, C. Driessen, T. Rudiger, K. Muller-Hermelink, V. Diehl, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group Blood, January 15, 2003; 101(2): 420 - 424. [Abstract] [Full Text] [PDF]
|
|